Maxine Taylor

发表

Drug Interactions for Low-Dose Inhaled Nemiralisib: A Case Study Integrating Modeling, In Vitro, and Clinical Investigations

A. Harrell, K. Riddell, Kunal S. Taskar, 2020, Drug Metabolism and Disposition.

Application of the Stable Isotope Label Approach in Clinical Development—Supporting Dissolution Specifications for a Commercial Tablet Product with Tafenoquine, a Long Half-life Compound

T. Ernest, N. Goyal, G. Koh, 2018, The AAPS Journal.

Navigating CYP1A Induction and Arylhydrocarbon Receptor Agonism in Drug Discovery. A Case History with S1P1 Agonists.

E. Demont, J. Witherington, Simon Taylor, 2015, Journal of medicinal chemistry.

Evaluation of a Three-Dimensional Primary Human Hepatocyte Spheroid Model: Adoption and Industrialization for the Enhanced Detection of Drug-Induced Liver Injury.

Tracy M Walker, Melanie Z Sakatis, Metul Patel, 2021, Chemical research in toxicology.

Pharmacokinetic Interactions between Tafenoquine and Dihydroartemisinin-Piperaquine or Artemether-Lumefantrine in Healthy Adult Subjects

N. Goyal, G. Koh, S. Duparc, 2016, Antimicrobial Agents and Chemotherapy.

Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial

J. Rubio, S. Krudsood, A. Llanos-Cuentas, 2016, Malaria Journal.

Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.

J. Ambroso, H. Ellens, M. Reese, 2012, Chemical research in toxicology.

Murine Oatp1a/1b Uptake Transporters Control Rosuvastatin Systemic Exposure Without Affecting Its Apparent Liver Exposure

E. van de Steeg, A. Schinkel, E. Wagenaar, 2013, Molecular Pharmacology.

The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2.

Hung‐Yuan Cheng, Stephen A. Smith, I. Stansfield, 2003, Bioorganic & medicinal chemistry letters.

Disposition and Metabolism of Darapladib, a Lipoprotein-Associated Phospholipase A2 Inhibitor, in Humans

H. Ellens, G. Young, A. Roberts, 2014, Drug Metabolism and Disposition.

Tafenoquine co-administered with dihydroartemisinin–piperaquine for the radical cure of Plasmodium vivax malaria (INSPECTOR): a randomised, placebo-controlled, efficacy and safety study

I. Elyazar, R. Noviyanti, D. Subekti, 2023, The Lancet. Infectious diseases.

A pharmacometrics approach to assess the feasibility of capillary microsampling to replace venous sampling in clinical studies: Tafenoquine case study

N. Goyal, S. Duparc, Sagar S. Bachhav, 2022, British journal of clinical pharmacology.

Application of the Stable Isotope Label Approach in Clinical Development—Supporting Dissolution Specifications for a Commercial Tablet Product with Tafenoquine, a Long Half-life Compound

T. Ernest, N. Goyal, G. Koh, 2018, The AAPS Journal.

Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial

J. Rubio, S. Krudsood, A. Llanos-Cuentas, 2016, Malaria Journal.

An integrated reactive metabolite evaluation approach to assess and reduce safety risk during drug discovery and development.

Jeffrey Ambroso, Eric Yang, J. Ambroso, 2011, Chemico-biological interactions.

The discovery of SB-435495. A potent, orally active inhibitor of lipoprotein-associated phospholipase A(2) for evaluation in man.

Hung‐Yuan Cheng, Stephen A. Smith, I. Stansfield, 2002, Bioorganic & medicinal chemistry letters.